Company / Working Capital
ImmunityBio, Inc. Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$253.1M
FY2025
5-year range
-$360.3M / $253.1M
FY2021-FY2025
Trend
+95.2%
vs FY2024
Sector context
#155 of 213
Health Care
What the data says
At $253M, ImmunityBio, Inc.'s working capital ranks #155 of 213 in the Health Care sector. Working Capital has fluctuated over the past 10 years, ranging from -$360M in FY2022 to $253M in FY2025.
Based on SEC 10-K filings.
$253M in FY2025 with a 5-year CAGR of +42.2%.
Improved from $236M to $253M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +42.2%
- 10-Year CAGR
- -
Sector benchmark
#155 of 213 in Health CareTop 73% of 213This company $253.1M Sector average $934.6M
▼
-72.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +42.2%, indicating consistent growth.
- In FY2025, working capital increased 95.2% year-over-year.
- Ranks #155 out of 213 companies in the Health Care sector.
- Lowest working capital in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -7.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $253.1M | +95.2% |
| FY2024 | $129.6M | -45.0% |
| FY2023 | $235.8M | +165.4% |
| FY2022 | -$360.3M | -939.8% |
| FY2021 | -$34.6M | -179.5% |
| FY2020 | $43.6M | -1.4% |
| FY2019 | $44.2M | -28.1% |
| FY2018 | $61.5M | -44.9% |
| FY2017 | $111.6M | -42.1% |
| FY2016 | $192.6M | -33.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026